Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
524 results
  • Teriflunomide induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. [Letter]
    Clin Exp Dermatol. 2020 Jun 17 [Online ahead of print]Choudhary R, Ashraf R, … Kumaran MS
  • A 27-year old female presented with a 3 day history of fever, itchy maculopapular rash progressing cephalocaudally and facial swelling. She was a known case of multiple sclerosis (MS) taking oral teriflunomide 14 mg for past 27 days. She was not taking any other drug. Symptom appeared 3 weeks after initiation of drug. Clinical examination revealed dusky maculopapular rash involving trunk (Figure …
  • COVID-19 in teriflunomide-treated patients with multiple sclerosis. [Journal Article]
    J Neurol. 2020 Jun 03 [Online ahead of print]Maghzi AH, Houtchens MK, … Bakshi R
  • The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequentl…
  • Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. [Review]
    Mult Scler Relat Disord. 2020 May 13; 43:102158.Vermersch P, Oh J, … Coyle PK
  • Multiple sclerosis (MS) is a chronic, immune-mediated, inflammatory disease affecting the white and gray matter of the central nervous system. Several disease modifying therapies (DMTs) have been shown to significantly reduce relapse rates, slow disability worsening, and modify the overall disease course of MS. Decision-making when initiating a DMT should be shared between the patient and physici…
  • A case of drug-induced bullous pemphigoid associated with teriflunomide: A patient with relapsing multiple sclerosis. [Case Reports]
    Mult Scler Relat Disord. 2020 May 15; 43:102157.Arslan D, Aksakal AB, … Tuncer MA
  • CONCLUSIONS: We report the first case of bullous drug reaction associated with teriflunomide. Multiple drugs have been implicated in the pathogenesis of the disease so far. It is important to point out some immunosuppressants may trigger autoimmune diseases like bullous pemphigoid.Considering recently reported skin reactions associated with teriflunomide, neurologists and patients should be careful on potential warning symptoms and signs of cutaneous drug reactions of this drug.
  • Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis. [Journal Article]
    Mult Scler Relat Disord. 2020 May 06; 43:102129.Muehler A, Peelen E, … Vitt D
  • CONCLUSIONS: The investigations highlighted that the desired selective immunomodulatory properties can be separated from general antiproliferative effects seen and related adverse events in first-generation DHODH inhibitors. Based on data obtained from a series of pre-clinical as well as phase 1 and phase 2 studies, IMU-838 is a promising next-generation candidate for the oral treatment of RRMS. However, this will need to be confirmed in the currently ongoing Phase 2 study in RRMS patients.
  • Teriflunomide, a potential novel cause of chronic active colitis. [Letter]
    Histopathology. 2020 Apr 23 [Online ahead of print]Kővári B, Zachs J, … Lauwers GY
  • Teriflunomide is a novel pyrimidine synthesis inhibitor which limits immune response by selectively blocking dihydroorotate dehydrogenase, required by rapidly dividing B and T lymphocytes [1]. It is indicated as a first-line treatment for relapsing-remitting multiple sclerosis (RRMS). The most common adverse reactions reported in patients receiving either 7 or 14 mg daily include headache (18% an…
New Search Next